FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers

Home / Blog / FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers
FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers
July 02, 2020July 2, 2020
0

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for people with inoperable or metastatic colorectal cancer with specific genetic features that denote a high mutation rate. The decision comes after promising findings from KEYNOTE-177 (NCT02563002), a Phase 3 trial in which Keytruda more than doubled the time patients lived without signs of disease progression, compared with standard chemotherapy, while lowering the rate of serious adverse events. With this approval,…

You must be logged in to read/download the full post.

The post FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers appeared first on BioNewsFeeds.